# A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

> **NCT03720548** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** LY3372993
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03720548
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-05-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720548, "A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03720548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*